Decoding The Surge: Palisade Bio (PALI) Shares On The Move
Decoding The Surge: Palisade Bio (PALI) Shares On The Move
The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug.
在本交易日中，Palisade Bio, Inc.（納斯達克股票代碼：PALI）的股價顯著上漲，上漲了21.46％，使其價值升至7.32美元。PALI股價的大幅上漲是在成功完成新藥開發分析之後出現的。
Today, Palisade Bio (PALI) has announced the successful conclusion of its analysis assessing the impact of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay. PALI-2108, an orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug developed by Palisade, targets patients afflicted with UC.
今天，Palisade Bio（PALI）宣佈其分析成功結束，該分析評估了生物活化的 PALI-2108 對全血（WB）檢測中腫瘤壞死因子α生成的影響。PALI-2108 是Palisade開發的一種口服、局部作用、結腸特異性磷酸二酯酶4（PDE4）抑制劑前藥，靶向UC患者。
The obtained data fortifies Palisade Bio's confidence in the robust anti-inflammatory capabilities of PALI-2108 in managing UC. The superior efficacy of PALI-2108, evidenced by its lower half-maximal inhibitory concentration (IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as an advanced therapeutic option for inflammatory bowel disease patients.
獲得的數據增強了 Palisade Bio 對 PALI-2108 在管理 UC 方面的強大抗炎能力的信心。與批准的PDE4抑制劑apremilast相比，其較低的半最大抑制濃度（IC50）證明了PALI-2108 的卓越療效，這凸顯了其作爲炎症性腸病患者先進治療選擇的潛力。
This comprehensive study involved WB samples from 14 clinically healthy adults, comprising five women and nine men. Twelve samples meeting the inclusion criteria were utilized for TNF-α measurement and IC50 value calculation. Donor whole blood underwent treatment with varied concentrations of PALI-2108 and two control compounds known for inhibiting the PDE4 pro-inflammatory pathway, subsequently being challenged with the pro-inflammatory molecule lipopolysaccharide (LPS).
這項全面的研究涉及來自14名臨床健康的成年人的WB樣本，包括5名女性和9名男性。使用了十二個符合納入標準的樣本進行腫瘤壞死因子α測量和IC50值計算。捐贈者的全血接受了不同濃度的 PALI-2108 和兩種已知可抑制 PDE4 促炎途徑的對照化合物的治療，隨後受到了促炎分子脂多糖（LPS）的挑戰。
Anti-inflammatory potency was determined by computing IC50 values for TNF-α inhibition. Results from the study showcased the efficacy of PALI-2108 in inhibiting LPS-induced TNF-α production in this ex-vivo peripheral whole blood assay. Pretreatment of human whole blood samples with bioactivated PALI-2108 led to a significant reduction in LPS-induced TNF-α production compared to non-pretreated samples.
抗炎效力是通過計算腫瘤壞死因子α抑制的IC50值來確定的。該研究的結果表明，在這項體外周全血分析中，PALI-2108 在抑制 LPS 誘導的腫瘤壞死因子-α產生方面的功效。與未經預處理的樣本相比，使用生物活化的 PALI-2108 對人體全血樣本進行預處理可顯著減少 LPS 誘導的腫瘤壞死因子α的產生。
The study was conducted in collaboration with Paraza Pharma, Inc., headquartered in Montreal, QC. Palisade Bio's exceptional operational performance is propelling the clinical advancement of PALI-2108 towards its first-in-human study, slated to commence later this year. Palisade Bio remains dedicated to advancing its innovative research endeavors aimed at enhancing the quality of life for UC patients and those affected by other inflammatory conditions.
該研究是與總部位於魁北克蒙特利爾的Paraza Pharma, Inc.合作進行的。Palisade Bio的卓越運營業績正在推動 PALI-2108 的臨床進展，邁向其首次人體研究，該研究定於今年晚些時候開始。Palisade Bio仍然致力於推進其創新研究工作，旨在提高UC患者和其他炎症性疾病患者的生活質量。
譯文內容由第三人軟體翻譯。